AMLX

Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. (AMLX) has 13 SEC Form 4 filings (14 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Jul 13, 2026.

The most active filer is Chief Legal Officer Mazzariello Gina with 4 filings. Insiders have net sold $1.7M over the trailing 6 months.

  • Industry:Biotechnology
  • CEO:Joshua Cohen
  • Employees:136
  • HQ:Cambridge, MA, US
  • IPO:2022-01-07

Insider Buying

$51K

reported purchases (SEC code P)

Insider Selling

$1.7M

reported sales (SEC code S)

Unique Insiders

6

in the rolling window

Market Cap

$2.5B

latest known value

Source
Mazzariello GinaFirst in 4 months
Sale$275KJul 13SEC ↗
Mazzariello GinaFirst in 4 months
Sale$264KJul 13SEC ↗
Firestone KarenFirst filing
Purchase$51KMay 26SEC ↗
Cohen Joshua BFirst filing
Sale$424KMar 4SEC ↗
Sale$99KMar 4SEC ↗
Sale$94KMar 4SEC ↗
Klee Justin B.First filing
Sale$424KMar 4SEC ↗
FRATES JAMES MFirst filing
Sale$115KMar 4SEC ↗
Mazzariello GinaFirst filing
Sale$48KFeb 25SEC ↗

Related companies

Amylyx Pharmaceuticals, Inc. is in the Healthcare sector.